A clinical-stage biopharmaceutical company approached Stellarix to get a technology and innovation overview in the allogeneic iPSCs segment. Our strategic intelligence helped the client gain a future outlook on allogeneic iPSCs development with HLA/MHC knockdown, reforming its market and business strategy.
Client Background:
Clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases.
Engagement Objective:
The objective of the engagement was to conduct a technology overview and start-up scouting in the domain of development of allogeneic iPSCs with HLA /MHC knockdown, and further differentiate them into neuronal cells. The study also included-
- The identification of innovative technologies and associated players in the domain of interest
- iPSCs technology overview, including key trends and cutting-edge innovations
- Details of technology providers (big players, SMEs, start-ups, universities, and hospitals) and a list of activities conducted by them
- Competitive benchmarking of key companies and associated technologies
Client Impact:
- The client acquired valuable insights into the cutting-edge and latest technologies on allogeneic iPSCs development with HLA/MHC knockdown, differentiated into neuronal cells, key companies (big players, SMEs, and start-ups), and research institutes in the domain of interest
- The client could delve into the future outlook of the allogeneic iPSCs and get an insightful and comparative landscape of the above
Outcome Snapshot:
